334 related articles for article (PubMed ID: 15638954)
1. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Fuster LM; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
6. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
8. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Sandler A
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Lin CC; Yang JC
Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
[TBL] [Abstract][Full Text] [Related]
12. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Bonomi P
Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807
[TBL] [Abstract][Full Text] [Related]
15. Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Reck M
Future Oncol; 2006 Feb; 2(1):47-51. PubMed ID: 16556072
[TBL] [Abstract][Full Text] [Related]
16. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
Herbst RS; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Yang X; Yang K; Kuang K
Curr Oncol Rep; 2014 Jun; 16(6):390. PubMed ID: 24807015
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib therapy for non-small cell lung cancer.
Birnbaum A; Ready N
Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
